GlassScriptPhysician profile
Manish Dhawan
NPI 1083618912
$28,307.97
in general payments reported to CMS, 2019-2025
88 companies · $4,619 in 2025
The $4,619 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,412 · 2020: $3,144 · 2021: $4,369 · 2022: $3,193 · 2023: $3,706 · 2024: $3,865 · 2025: $4,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Long Term Medical Supply Or Device Loan: $1,280 · Education: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,529.18 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $381.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,662.41 | 2019-2025 | |
| Mckesson Specialty Care Distribution, LLC | $2,641.93 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,479.73 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $1,370.48 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,369.19 | 2019-2025 | Darzalex, Erleada, Talvey |
| Daiichi Sankyo INC. | $959.95 | 2019-2025 | Enhertu, Injectafer |
| Astellas Pharma US INC | $901.27 | 2019-2025 | Padcev, Vyloy, Xospata |
| E.R. Squibb & Sons, L.L.C. | $823.69 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Pfizer INC. | $806.36 | 2019-2025 | |
| Amgen INC. | $788.70 | 2019-2023 | Vectibix, Nplate, Kyprolis |
| Incyte Corporation | $728.69 | 2019-2025 | Jakafi, Monjuvi |
| Eisai INC. | $694.23 | 2019-2025 | |
| Celgene Corporation | $662.90 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Genzyme Corporation | $654.89 | 2019-2025 | |
| Puma Biotechnology, INC. | $624.68 | 2019-2024 |
Show all 88 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Dhawan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.